𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3

✍ Scribed by Jonas Lundkvist; Nils Wilking; Stig Holmberg; Linus Jönsson

Publisher
Springer US
Year
2006
Tongue
English
Weight
368 KB
Volume
102
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of switching to exeme
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

Benefit and projected cost-effectiveness
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer
✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio